Baguley B C
Cancer Research Laboratory, University of Auckland Medical School, New Zealand.
Biophys Chem. 1990 Apr;35(2-3):203-12. doi: 10.1016/0301-4622(90)80009-v.
Amsacrine is a DNA intercalating agent which is active against a number of tumours in mice and is used for the treatment of leukaemia in humans. In its DNA-bound form, amsacrine efficiently quenches the fluorescence of ethidium. Fluorescence lifetime studies demonstrate two populations of DNA-bound ethidium. The first, whose fluorescence lifetime is constant at approx. 3 ns and whose proportion increases with increasing amsacrine binding ratio, may comprise molecules bound in close proximity to amsacrine. The second, whose fluorescence lifetime is longer and variable (10-24 ns) and whose proportion decreases with increasing amsacrine binding ratio, may comprise molecules three or more base-pairs away from ethidium. Studies with a number of derivatives of 9-anilinoacridine containing different anilino substituents suggest that the observed wide variation in quenching capacity is correlated with the magnitude of the substituent dipole moment in a particular direction. Consideration of the geometry of the DNA-binding complex indicates that the negative pole of a dipole established in the anilino ring is directed towards a positively charged site on the ethidium molecule. Quenching of ethidium fluorescence may therefore occur where an electron-transfer complex has formed between ethidium and amsacrine molecules. To ascertain whether electron-transfer complex formation is biologically important in the amsacrine series, ethidium quenching has been quantitated and compared with activity against a transplantable neoplasm in mice, the Lewis lung carcinoma. Compounds which strongly quench ethidium fluorescence are in general highly active antitumour agents. The results are discussed in terms of a model where amsacrine has both a DNA-binding and a protein-binding domain, the latter possibly interacting by formation of an electron-transfer complex. The most likely protein-binding domain is on the enzyme topoisomerase II, the target for its cytotoxic activity.
安吖啶是一种DNA嵌入剂,对小鼠体内多种肿瘤具有活性,用于治疗人类白血病。在其与DNA结合的形式中,安吖啶能有效淬灭溴化乙锭的荧光。荧光寿命研究表明存在两种与DNA结合的溴化乙锭群体。第一种,其荧光寿命约为3 ns且恒定,其比例随安吖啶结合率增加而升高,可能包含与安吖啶紧密相邻结合的分子。第二种,其荧光寿命较长且可变(10 - 24 ns),其比例随安吖啶结合率增加而降低,可能包含与溴化乙锭相隔三个或更多碱基对的分子。对含有不同苯胺取代基的9 - 苯胺基吖啶的多种衍生物的研究表明,观察到的淬灭能力的广泛变化与特定方向上取代基偶极矩的大小相关。对DNA结合复合物几何结构的考虑表明,在苯胺环中形成的偶极的负极指向溴化乙锭分子上的一个带正电的位点。因此,当在溴化乙锭和安吖啶分子之间形成电子转移复合物时,可能会发生溴化乙锭荧光的淬灭。为了确定电子转移复合物的形成在安吖啶系列中是否具有生物学重要性已对溴化乙锭淬灭进行了定量,并与对小鼠可移植肿瘤刘易斯肺癌的活性进行了比较。强烈淬灭溴化乙锭荧光的化合物通常是高活性抗肿瘤剂。根据一个模型对结果进行了讨论,在该模型中安吖啶具有一个DNA结合结构域和一个蛋白质结合结构域,后者可能通过形成电子转移复合物相互作用。最可能的蛋白质结合结构域位于酶拓扑异构酶II上,这是其细胞毒性活性的靶点。